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Abstract 
Objective: To test several key glucocorticoid genes that are enhanced in lung development for 
associations with respiratory distress syndrome (RDS) after antenatal corticosteroid use. 
Methods: A prospective cohort of women received betamethasone to accelerate fetal lung maturity for 
threatened preterm delivery. DNA was obtained from mothers and newborns. Neonatal RDS was the 
primary outcome. Genotyping for SNPs in 68 glucocorticoid genes found to be differentially expressed 
during lung development was performed. Multivariable analysis tested for associations of SNPs in the 
candidate genes with RDS.  
Results: Genotypic results for 867 SNPs in 96 mothers and 73 babies were included. 39 babies (53.4%) 
developed RDS. Maternal SNPs in the CENPE, GLRX, CD9, and AURKA genes provided evidence of 
association with RDS (p<0.01). In newborns, SNPs in COL4A3, BHLHE40, and SRGN provided 
evidence of association with RDS (p<0.01). 
Conclusion: SNPs in several glucocorticoid responsive genes suggest association with neonatal RDS 
after antenatal corticosteroid use. 
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Introduction 
 The benefits of antenatal corticosteroids for the preterm infant are clear. The reduction in 
mortality and morbidity has been a major advance in reducing the cost of preterm birth.1 As with many 
therapeutics, however, not all babies receive the same benefit from antenatal corticosteroids.2 We have 
previously demonstrated that genetic polymorphisms in key drug metabolism and steroid receptor 
pathways can account for some of the differences in neonatal respiratory outcomes.3,4 
 The pathways of steroid response are complex. While our prior studies demonstrated that single 
nucleotide polymorphisms (SNPs) in adenylate cyclase 9 (ADCY9) and Importin 13 (IPO13) are 
associated with respiratory distress syndrome (RDS),3,4 reports from other complex respiratory diseases 
such as asthma, have uncovered multiple genes involved in respiratory response to steroids.5,6 A group 
of steroid genes have been demonstrated to be up-regulated and important in human fetal lung 
development.7 The importance of these steroid pathway genes in disease development, however, is not 
yet known. A larger scale investigation of the role of steroid pathway genes in the development of RDS 
in a population receiving antenatal corticosteroids has not been performed according to our knowledge.  
 The objective of this study was to test for associations of specific key glucocorticoid genes that 
are differentially expressed during lung development with neonatal RDS after antenatal corticosteroid 
use for anticipated preterm birth. The hypothesis was that key steroid genes in either the mother or 
developing baby would impact the effectiveness of antenatal corticosteroids that thus would be 
associated with development of RDS. Finding key steroid genes associated with RDS may then enable 
better understanding of how antenatal corticosteroids enhance lung maturation in an effort to further 
improve this therapy.  
Methods 
Subjects and Samples 
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 This was a secondary analysis of a betamethasone (BMZ) pharmacogenetics cohort study. The 
acquisition of the cohort and samples has been documented elsewhere.4 Briefly, women admitted to the 
hospital with threatened preterm delivery who received BMZ were recruited to the study. Informed 
consent was obtained for all women enrolled and the governing Institutional Review Board approved the 
study. Informed consent was obtained from all participants who were enrolled prospectively as they 
were admitted to the hospital for BMZ administration. Participants had to be at least 18 years old and at 
least 23 weeks but less than 34 weeks gestation. Exclusion criteria included known fetal anomaly or 
inability to provide consent.  Standard clinical care at the providers’ discretion was provided to the 
woman and standard neonatal resuscitation and care practices were provided by the pediatric/neonatal 
services.  Women could have received a rescue course of BMZ per routine clinical care if the clinical 
course warranted. No restrictions were placed on clinical provider care as this was an observational 
cohort study. The neonatal outcome of RDS was diagnosed by the pediatricians following standard 
NICHD Neonatal Research Network criteria.8  
 Maternal DNA was obtained from whole blood or from a salivary sample if unable to obtain 
blood. Neonatal DNA was obtained from umbilical cord blood or from buccal swabs if unable to obtain 
umbilical cord blood at the time of delivery. Salivary or buccal samples were collected and processed 
using the Oragene® saliva kit (DNA Genotek). DNA isolation was done according to manufacturer 
instructions.  Samples were frozen at -80 ̊ C until quantified. DNA was extracted from blood samples 
using the QIAamp® DNA mini kits (Qiagen Inc., Valencia, CA).  Manufacturer spin protocol 
instructions were followed for all kits. When manufacturer protocols listed steps for highly concentrated 
DNA, those steps were followed.  Isolated DNA was transferred into 1.2mL cryovials and all samples 
were stored at -80 ̊ C until quantified. All quantification was completed using Quant-iTTM Fluorometer 
and Quant-iTTM dsDNA Broad Range Assay kit (Life Technologies, Inc., Carlsbad, CA) 
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Glucocorticoid gene selection 
 We determined a corticosteroid gene set by identifying genes that were differentially expressed 
between dexamethasone and sham treated immortalized lymphoblastoid cell lines obtained from 
adolescent subjects with mild-moderate persistent asthma participating in the Childhood Asthma 
Management Program (CAMP).9,10  We then identified which of these glucocorticoid genes were 
enriched in human lung development using human fetal lung tissue samples from the pseudoglandular 
and canalicular stages of lung development. Briefly, using genome-wide gene expression arrays, 
generated from 36 human fetal lung tissue samples (post-conception ages 7-26 weeks),11 we next tested 
whether the identified steroid response genes were enriched during early human fetal lung development. 
To do this, principal components analysis (PCA) was performed using the gene expression profiles from 
human fetal lung tissue. The principal component (PC) that was most highly correlated with gestational 
age was identified.  A chi square test was performed to determine whether the top 5% of genes 
contributing to the PC most highly associated with gestational age was enriched for genes in the steroid 
response pathway.  In total, 68 genes were differentially expressed at genome-wide significance in 
CAMP cell lines and were enriched during human lung development and thus were included in the 
corticosteroid gene set. (Table 1) The selection of these genes was done as part of a different project. 
The project described in this current study utilized the gene set that was differentially expressed by 
treatment response in asthmatic subjects and demonstrated enrichment during lung development.12 
Genotyping 
 Genotyping for the 68 glucocorticoid response genes previously found to be enhanced in human 
fetal lung development7 was performed using the Affymetrix Axiom® Genome-Wide LAT Array (Santa 
Clara, CA).  The Axiom array includes 818,154 probe sets. Non-degraded DNA from the mothers and 
infants was prepared at concentrations of 15ng/µL and placed into 96-well plates according to the 
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Affymetrix Axiom® instructions. Degradation of DNA samples was assessed by agarose gel 
electrophoresis. The genome-wide array was utilized as the most cost-effective method to interrogate the 
number of genes in the planned analysis. Table 1 lists the genes analyzed. DNA samples from the 
original cohort that did not have enough volume or could not achieve a high enough concentration for 
the array were excluded from this study (n=13 women). 
Statistical analysis 
 Given the sample sizes, we only performed analyses for the phenotype of RDS. Analyses were 
performed testing two hypotheses. The first was that the susceptibility for RDS was associated with 
maternal genetic variants. The second was that susceptibility for RDS was associated with genetic 
variants in the baby. For each SNP, we tested whether there was evidence for an association in the 
mothers and then we also tested for an association in the infant.  
In addition to the previously completed sample Quality Control (QC), SNP QC was also 
performed. SNPs were removed if their genotyping rate fell below 95% completeness and if the Hardy 
Weinberg Equilibrium p-value was less than 10-4. Because of the small sample size, analyses only 
included SNPs having a minor allele frequency of at least 10%. Because this was a racially diverse 
sample, we included two principal components (PC1 and PC2) as covariates to adjust for population 
stratification in the logistic regression model created. These principal components were derived from the 
Axiom SNP data by using EIGENSOFT.13,14 In addition, we also included gestational age as a covariate 
in the model.  This is an exploratory study and so we used a relatively liberal threshold of p<0.01 to 
identify SNPs of interest. 
68 genes were the initial focus of the model analysis. SNPs within these genes were the scope of 
this analysis. A SNP was defined as being ‘in the gene’ if it is within ±20kb of that gene. This is 
typically done by our group to ensure that regulatory regions are not missed.15 Because samples sizes of 
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both models are very small, SNP QC was calculated separately for each sample. There were a total of 
1,903 SNPs in these 68 genes. For analyses of maternal effects and genetic effects in the baby, 820 and 
837 SNPs passed QC, respectively (867 SNPs in total). Original array files were transformed in PLINK 
(V1.07; http://pngu.mgh.harvard.edu/purcell/plink/) format and initial QC was performed. Only samples 
passing gender (PLINK option – check sex) and relationship (PLINK option – genome to calculate 
pairwise IBD estimation) checks were included. We then reviewed the population stratification plot 
anchored with the standard HapMap samples by using PC1 and PC2 calculated from EIGENSOFT13,14 
for ancestry and noted concordance with self-reported race/ethnicity. 
Results 
The overall characteristics of the cohort are reported elsewhere.4 Briefly, women in the original 
cohort had a mean maternal age of 26.5 years-old, had a mean parity of 1.5 and a mean gestational age 
at receiving the first dose of BMZ of 28.8±3.3 weeks gestation. From the initial cohort of 109 women 
and 117 neonates, 13 maternal samples were excluded if the DNA failed QC or did not have high 
enough concentrations or quantity for the GWAS array. A total of 96 mother-infant pairs remained; 32 
women had babies diagnosed with RDS and are referred to here as “cases” and 64 women had babies 
without RDS and are termed “controls”. When testing the hypothesis in the babies, the sample included 
39 cases with RDS and 34 controls without RDS. The mean maternal age of this cohort was 25.9±6.2 
years.  The mean gestational age at receiving BMZ was 29.2±3.1 weeks and the mean gestational age at 
delivery was 31.8±3.8 weeks. The mean number of days from BMZ initiation to delivery was 24.7±23.4 
days. Only 5 women (5.2%) received a rescue dose of BMZ. The ethnic/racial distribution was: 
Caucasian 46 (47.9%); African American 30 (31.2%); Hispanic 16 (16.7%), Mixed 2 (2.1%), and Indian 
1 (1.0%) and Other 1 (1.0%). These data for the subgroup reported here were not different from the 
overall original cohort. No women had adverse effects of BMZ injections. 
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Table 2 displays those SNPs that provided evidence of association with neonatal RDS in either 
the mother or the baby. All association measures are adjusted, controlling for gestational age at delivery. 
They are not, however, corrected for multiple comparisons. Maternal SNPs in the CENPE, GLRX, CD9, 
and AURKA genes provided evidence of association with RDS (Odds Ratio (OR), 95% Confidence 
Intervals respectively: 0.34 (0.16-0.74); 2.24 (1.24-4.03); 2.74 (1.35-5.56), 3.60 (1.58-8.20)). In the 
babies, SNPs in COL4A3, BHLHE40, CENPE, and SRGN provided evidence of association with RDS 
(OR (95% CI) respectively: 8.07 (1.68-38.76); 4.08 (1.46-11.36); 0.27 (0.09-0.77); 6.17 (1.66-23.01)). 
Due to sample size issues, we only controlled for gestational age at delivery, the most predictive variable 
for RDS. We were unable to incorporate other clinical variables such as infant gender into the current 
model. 
Comment 
 We have shown that glucocorticoid genes that are enriched during the pseudoglandular and 
canalicular stages of early human lung development harbor polymorphisms that are associated with RDS 
in newborn infants. . Our results suggest that this set of glucocorticoid genes appear to be important in 
the pseudoglandular and early canalicular stages of lung development and that abnormal expression of 
these genes may result in physiologic changes in the structure and/or function of the lung that result in 
an increase in in post-natal RDS.  Furthermore, our data indicate that in women who received antenatal 
corticosteroid therapy, both the maternal and fetal genotypes in steroid response genes show evidence of 
association with RDS. The finding of promising genes in both the mother and infant is consistent with 
other findings.3,4  These findings may provide evidence for the fetal origin of RDS. These findings 
complement our prior work in that this study specifically looked at a set of genes known to be enriched 
in the developing lung and go beyond the glucocorticoid receptor pathways we reported previously.3,4 
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SNPs in these genes may affect how BMZ acts at the level of the developing fetal lung. Many of 
these steroid responsive genes are in transcriptional pathways.   The maternal significant SNPs are 
involved in maintaining chromosome stability (CENPE), and cell cycle regulation and progression 
(AURKA). In addition, GLXR is involved in signaling pathways and CD9 is important in cell adhesion, 
motility and differentiation. All of the associated SNPs increased the risk of RDS except for CENPE 
(rs6533058) which had a protective effect. The meaning of this finding is unclear given that this gene is 
associated with maintaining chromosome stability. We were unable to find other reports of clinical or 
physiological implications for this particular SNP. While these promising SNPs are from different 
pathways, more work needs to be done to ascertain the mechanistic link with delivery of the premature 
fetal lung. The fact that these genes were also found to be enhanced in response to dexamethasone in a 
large asthma data set and are now associated with premature infant respiratory distress strengthens the 
potential importance of these genes in normal development and function of the human lung and in 
glucocorticoid response. 
Similarly, the fetal SNPs associated with RDS are in seemingly different pathways, with 
COL4A3 being a structural component of collagen, SRGN regulating hematopoietic cell proteoglycan, 
CENP1 maintaining chromosome stability, and BHLHE40 helping to control cell differentiation. As 
current mechanisms of fetal lung maturation rely on the differentiation of surfactant-producing 
pneumocytes, it is possible that BHLHE40 may be an important gene in this regard. Of note, all four of 
these genes were identified to be in the top 5% of genes involved in human lung development using 
PCA and were significantly differentially expressed between the pseudoglandular and canalicular stages 
of lung development.  COL4A3 expression was significantly higher in the pseudoglandular stage of 
development when compared to the canalicular stage (p=0.04). However, SRGN expression was 
significantly higher in the canalicular period compared to the pseudoglandular stage (p=0.008). 
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Furhermore, CENPE also demonstrated significantly higher gene expression in the canalicular period 
(p=0.01), as did the BHLHE40 gene (0.009).   
We identified that both maternal and infant SNPs in the Centromeric protein E gene (CENPE) 
were associated with the development of RDS in the newborn.  CENPE is located on chromosome 4q24.  
It encodes a large kinetochore-associated kinesin-like motor protein required for spindle microtubule 
capture and attachment at the kinetochore during cell division.17 Previous studies have demonstrated that 
somatic mutations in this gene result in an increased risk of familial lung cancer.18  Although little is 
known about the impact of CENPE in the development of RDS, its role in the maintenance of 
chromosomal stability may have implications for a variety of chronic respiratory diseases with 
developmental origins.  Additional studies will be needed to identify the precise role of CENPE in the 
development of RDS. 
The strength of this work is that it extends findings of respiratory disease (asthma) steroid 
responsive genes to the area of fetal development genetics and pharmacogenetics. The consistent 
findings that some of these genes are also associated with neonatal RDS lend credence to their being 
important in lung development and function.  In addition, the odd ratios for these associations are large. 
Another strength of the study is the rigorous QC that the analysis undertook to ensure that the likelihood 
of erroneous associations was lessened. 
The study is limited by its size. In addition, the use of gene expression profiles from asthmatic 
subjects in CAMP to identify the initial glucocorticoid gene set may have identified a group of genes 
that are implicated in asthma pathogenesis and treatment response as opposed to genes involved in RDS.  
Although we recognize this as a limitation, the use of this cohort would have biased our results towards 
the null and is less likely to have resulted in false positive results. While we were able to control for 
gestational age at delivery, we could not control for other variables in the multivariable model. As other 
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factors like infant gender, ethnicity, and diabetes may also be associated with RDS, in future studies a 
larger sample size would be needed to adjust for these confounders without the loss of statistical power. 
In addition, the smaller sample size did not allow us to look at other outcomes including chronic lung 
disease of the infant, surfactant use, and total respiratory support days. Furthermore, our results are 
modest and must be replicated in additional samples from a validation cohort. These genes may also be 
associated with preterm birth and not simply RDS. Other genetic studies looking at SNPs associated 
with preterm birth have not noted associations with these genes.19-27 Because we had access to 
immortalized cell lines in asthmatic populations, we used these data to identify our corticosteroid gene 
set. However, using differential expression in an asthmatic population is a potential limitation as some 
corticosteroid genes that are important in RDS may not have been identified in this patient population. 
Gene expression studies of these SNPs in the cell lines of interest are also needed to further understand 
these findings. 
The study of pharmacogenetics in pregnancy is still in its infancy. Pharmacogenetics in asthma 
therapy is somewhat more advanced.5 Utilizing the homology in the complex respiratory disease of 
asthma with the development of another complex developmental respiratory disease in RDS is 
appealing.  As antenatal corticosteroids are utilized in both conditions- to treat one and prevent the 
other- pharmacogenetic analogies may become evident. Steroid pathway genes of impact should 
continue to be studied to help unlock the mechanisms of fetal lung development and the prevention of 
RDS. Only then can antenatal corticosteroid pharmacogenetics and the hope of more individualized 
pharmacotherapy move closer to realities. 
In conclusion, several maternal and infant genes in steroid responsive pathways appear 
associated with the development of neonatal RDS. Further development of these pathways and the 
mechanisms by which they may influence fetal lung development are needed. The use of genetic 
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analysis tools and informatics can help advance our understanding of therapeutic response in obstetrics. 
By better understanding fetal lung development and the genetic influence on the pathways of maturation 
we may realize further advances in optimizing fetal lung development in preterm birth. 
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Table 1: List of steroid genes enriched in lung development analyzed in the study 
 
Gene Name Function Locus EntrezID
KLF9 
Kruppel-like factor 9 transcription factor binds 
to GC box in promoter 9q13 687
TSPO 
Translocator protein mitochondrial protein 
factor in flow of 
cholesterol to permit 
initiation of steroid 
synthesis 22q13.31 706
CDKN2C 
Cyclin-dependent kinase 
inhibitor 2C 
functions as cell growth 
regulator 1p32 1031
COL4A3 
Collagen type IV, alpha 3 
(Goodpasture antigen) 
structural component 
collagen 2q36 1285
FCER1G 
Fc fragment IgE gamma 
polypeptide receptor 
receptor involved in 
allergic reactions 1q23 2207
IGFBP4 
Insulin-like growth factor 
binding protein 4 
prolongs the half-life of 
IGFs 17q12 3487
ISG20 
Interferon stimulated 
exonuclease gene 
ribosome biogenesis, 
degrades single-stranded 
RNA 15q26 3669
MAL 
T-cell differentiation 
protein 
role in formation, 
stabilization, and 
maintenance of 
membrane 
microdomaines 2q13 4118
SRGN 
Serglycin hematopoietic cell 
granule proteoglycan 10q22.1 5552
S100A6 
S100 calcium binding 
protein A6 
cell cycle progression 
and differentiation 1q21 6277
TUBA4A Tubulin alpha 4a microtubule formation 2q35 7277
TUBB4 Tubulin beta 4 microtubule formation 19p13.3 10382
RND1 
Rho family GTPase 1 regulates organization of 
actin cytoskeleton 12q12 27289
BIRC3 
Baculoviral IAP repeat 
containing 3 
inhibits apoptosis 
11q22 330
BCL3 B-cell CLL/lymphoma 3 proto-oncogene 19q13.1 602
KLF5 
Kruppel-like factor 5 transcription factor binds 
to GC box in promoter 13q22.1 688
NFKBIA 
Nuclear factor of kappa 
light polypeptide gene 
enhancer B-cell inhibitor 
alpha 
involved in 
inflammatory response 
14q13 4792
RGS1 
Regulator of G-protein 
signaling 1 
G-protein signaling 
family 1q31 5996
RRAD 
Ras-related associated with 
diabetes 
voltage-regulate Ca 
channels, inhibits 
phosphorylation 16q22 6236
TNFAIP3 Tumor necrosis factor inhibits apoptosis; 6q23 7128
17 
 
alpha-induced protein 3 involved in immune and 
inflammatory response 
RASSF7 
Ras associated domain 
family member 7 
regulates microtubule 
cytoskeleton 11p15.5 8045
BHLHE40 
Basic helix-loop-helix 
family member e40 
control of cell 
differentiation 3p26 8553
IRS2 
Insulin receptor substrate 2 mediates effects of 
insulin and other 
cytokines 13q34 8660
SPRY1 
Sprouty homolog 1 fibroblast growth factor 
antagonist, may 
negatively modulate 
respiratory 
organogenesis 4q28.1 10252
AGPAT2 
1-acylglycerol-3-phosphate 
O-acytransferase 2 
controls 2nd step in 
phospholipid 
biosynthesis 9q34.3 10555
UBE2T 
Ubiquitin-conjugating 
enzyme E2T 
regulate cell pathways 
and proteins 1q32.1 29089
C5orf32 
Cysteine-rich 
transmembrane module 
containing 1 
choromosome 5 open 
reading frame protein 
5q31.3 84418
E2F7 
E2F transcription factor 7 regulation of cell cycle 
progression 12q21.2 144455
FKBP5 
FK506 binding protein 5 immunoregulation and 
basic cellular processes 6p21.31 2289
GLRX 
Glutaredoxin antioxidant defense 
system and signaling 
pathways 5q14 2745
GUCY1A3 
Guanylate cyclase 1 alpha 3 conversion of GTP to 
GMP, regulation of cell 
hyperplasia and 
differentiation 4q31.3 2982
LGALS3 
Lectin galactoside-binding 
soluble 3 
apoptosis, cell adhesion, 
innate immunity 14q22.3 3958
MDK 
Midkine promotes cell growth, 
angiogenesis 11p11.2 4192
ENC1 
Ectodermal-neural cortex 1 oxidative stress response 
as transcription regulator 5q13 8507
ZEB2 
Zinc finger E-box binding 
homeobox 2 
DNA-binding 
transcriptional repressor 2q22.3 9839
MACF1 
Microtubule-actin 
crosslinking factor 1 
cytoskeletal protein; 
wound healing and 
epidermal cell migration 1p32 23499
SLC39A6 
Solute carrier family 39 
member 6 
zinc influx transporter 
18q12.2 25800
ERRFI1 
ERBB receptor feedback 
inhibitor 1 
important in prenatal 
lung development; 
modulates response to 
steroid hormones in 1p36 54206
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uterus 
DDIT4 
DNA-damage-inducible 
transcript 4 
inhibits cell growth 
10q26.12 54541
KIAA1524 
Cancerous inhibitor of 
PP2A 
oncoprotein, promotes 
cell growth 3q13.13 57650
AHNAK 
AHNAK nucleoprotein neuronal cell 
differentiation 11q12.2 79026
C7orf23 
Chromosome 7 open 
reading frame 23 
chromosome 7 open 
reading frame protein 7q21.1 79161
ELOVL7 
ELOVL fatty acid elongase 
7 
synthesis of very long 
chain fatty acids 5q12.1 79993
CCNB1 
Cyclin B1 mitosis regulator at the 
G2/M transition 5q12 891
CD9 
CD9 molecule cell adhesion, motility, 
and differentiation 12p13.3 928
CEBPD 
CCAAT/enhancer binding 
protein delta 
regulation of genes 
involved in immune and 
inflammatory response 
and macrophage 
activation 8p11 1052
CENPE 
Centromere protein E maintenance of 
chromosomal stability 4q24 1062
DUSP1 
Dual specificity 
phosphatase 1 
cellular response to 
environmental stress 5q34 1843
HLA-DMA 
Major histocompatibility 
complex class II, DM alpha 
acquisition of antigenic 
peptides 6p21.3 3108
PDK4 
Pyruvate dehydrogenase 
kinase isozyme 4 
regulation of glucose 
metabolism 7q21.3 5166
PLK1 
Polo-like kinase 1 regulator of cell cycle 
progression 16p12.2 5347
SFTPD 
Surfactant protein D lung defense againt 
inhaled microorganisms 10q22.2 6441
AURKA 
Aurora kinase A cell cycle regulation and 
progression 20q13 6790
CDC7 
Cell division cycle 7 
homolog 
critical for G1/S 
transition 1p22 8317
VAMP8 
Vessicle-associated 
membrane protein 8 
transport vesicle 
membranes 2p12 8673
TNFSF10 
Tumor necrosis factor 
ligand superfamily member 
10 
induces apoptosis 
3q26  8743
IER3 
Immediate early response 3 protection against 
apoptosis 6p21.3 8870
CCNB2 
Cyclin B2 Cell cycle control at 
G2/M transition 15q22.2 9133
SPAG5 
Sperm associated antigen 5 component of mitotic 
spindle 17q11.2 10615
TXNIP 
Thioredoxin interacting 
protein 
oxidative stress mediator 
1q21.1 10628
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DKFZP564O0823 
Prostate androgen-regulated 
mucin-like protein 
apoptosis resistance 4q13.3-
q21.3 25849
DEPDC1 
DEP domain containing 1 transcriptional 
corepressor 1p31.2 55635
CENPK Centromere protein K mitotic progression 5p15.2 64105
VASH2 Vasohibin 2 angiogenesis inhibitor 1q32.3 79805
C13orf34 
Bora, aurora kinase A 
activator 
activates onset of mitosis 
13q22.1 79866
CDCA3 
Cell division cycle 
associated 3 
required for entry into 
mitosis 12p13 83461
SGOL1 Shugoshin-like 1 chromosome adhesion 3p24.3 151648
TUBB2B 
Tubulin beta 2B major component of 
microtubules 6p25 347733
Names and descriptions functions from GeneCards Human Genome Compendium (www.genecards.org) 
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Table 2: Summary of steroid genotypes associated with neonatal RDS 
SNP Chr BP Gene 
Baby 
Minor 
Allele 
Frequency 
aOR 
(95% 
CI) Baby 
p-value 
Mother 
Minor 
Allele 
Frequency 
aOR 
(95% 
CI) Mother 
p-value 
rs12621551 2 228,118,403 COL4A3 0.17 
8.07 
(1.68-
38.76) 0.0091 0.21 
2.02 
(0.86-
4.78) 0.1082 
rs7610825 3 5,037,635 BHLHE40(10kb) 0.49 
4.08 
(1.46-
11.36) 0.0072 0.40 
1.42 
(0.78-
2.62) 0.2547 
rs6533058 4 104,130,986 CENPE(11kb) 0.47 
0.27 
(0.09-
0.77) 0.0145 0.41 
0.34 
(0.16-
0.74) 0.0067 
rs6871090 5 95,133,586 GLRX(15kb) 0.37 
0.54 
(0.21-
1.37) 0.1930 0.37 
2.24 
(1.24-
4.03) 0.0072 
rs17473271 10 70,848,902 SRGN 0.19 
6.17 
(1.66-
23.01) 0.0067 0.18 
1.25 
(0.57-
2.81) 0.5693 
rs735885 12 6,312,663 CD9 0.46 
1.78 
(0.67-
4.73) 0.2452 0.37 
2.74 
(1.35-
5.56) 0.0054 
rs6064387 20 54,968,159 AURKA 0.43 
1.42 
(0.57-
3.58) 0.4535 0.41 
3.60 
(1.58-
8.20) 0.0023 
rs6064389 20 54,968,735 AURKA 0.40 
1.35 
(0.54-
3.35) 0.5198 0.37 
2.67 
(1.27-
5.64) 0.0098 
rs6064391 20 54,971,386 AURKA 0.41 
1.43 
(0.64- 0.3779 0.38 
2.56 
(1.26- 0.0094 
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3.19) 5.22) 
Note: In the column titled “gene”, the numbers in parentheses indicate the distance from the SNP to the gene. All other SNPs 
are within the gene listed in that column. Adjusted Odds Ratios (aOR) and 95% Confidence Intervals (CI) are for the listed 
SNP compared to the wild type. The aORs were generated controlling for gestational age at delivery. Results are only listed 
for genes with p<0.01 for association. 
 
 
 
